Dennis Karl Huang - Mar 1, 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
EVP, Chief Technical Operations Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Mar 1, 2024
Transactions value $
-$25,234
Form type
4
Date filed
3/5/2024, 08:17 PM
Previous filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +17.8K +27.51% $0.00 82.5K Mar 1, 2024 Direct F1
transaction RARE Common Stock Award $0 +957 +1.16% $0.00 83.5K Mar 1, 2024 Direct F2
transaction RARE Common Stock Tax liability -$25.2K -470 -0.56% $53.69 83K Mar 1, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +31.4K $0.00 31.4K Mar 1, 2024 Common Stock 31.4K $53.69 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2 Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric.
F3 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F5 On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Remarks:

EVP, Chief Technical Operations Officer